Skip to content

Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in Kenya

A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00830622
Enrollment
536
Registered
2009-01-28
Start date
2007-05-31
Completion date
2010-03-31
Last updated
2010-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, HIV, HIV Infections

Keywords

HIV/AIDS, Adherence, Antiretroviral Therapy, ART, ARV, Mobile phone, cell phone, telephone, Text message, SMS, Telemedicine, Africa, Resource-limited setting, Counseling, support, treatment experienced

Brief summary

A clinical study to evaluate the use of cell phones to support drug adherence and follow-up of patients taking antiretroviral therapy (ART) for treatment of HIV. The intervention involves health-care providers sending regular short-message-service (SMS) text messages to patients and following up their responses. The hypothesis is that the cell phone intervention will improve ART adherence and health outcomes compared with the current standard of care.

Detailed description

This RCT study focuses on enrolling and following patients initiating ART. Note, a second parallel prospective cohort study enrolls and follows ART experienced patients who have already been taking ART for at least one year before and after the same intervention.

Interventions

Participant receives weekly SMS text messages from the health care provider.

Sponsors

University of Nairobi
CollaboratorOTHER
University of Manitoba
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV infected and starting antiretroviral therapy * Adequate (daily) access to a cell phone * Intending to attend the enrollment clinic for 2 years * Consent to participate

Exclusion criteria

* Not meeting inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Adherence to ART and HIV RNA suppression6,12 monthsAlthough many patients are seen every 3 months, study visits with questionnaires and viral load are completed at 0, 6, and 12 month scheduled follow-up visits.

Secondary

MeasureTime frame
Retention6, 12 months
Quality of Life (SF-12)3, 6, 9, 12 months
Health (CD4, weight, progression to AIDS, all cause mortality)6, 12 months

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026